The effects of antacids on the absorption of enteric-coated phenylbutazone (butacote).
Phenylbutazone bioavailability from an enteric-coated formulation (Butacote) has been studied in normal volunteers following ingestion of a single 200 mg dose with water, aluminium hydroxide and magnesium trisilicate. No significant alteration in bioavailability of phenylbutazone from Butacote was noted in the presence of the antacids.
D000328:Adult; D000536:Aluminum Hydroxide / Q000008:administration & dosage / Q000097:blood; D000863:Antacids / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008274:Magnesium / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology; D008297:Male; D010653:Phenylbutazone / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D012824:Silicic Acid / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology; D013608:Tablets, Enteric-Coated
D000863:Antacids; D013608:Tablets, Enteric-Coated; D012824:Silicic Acid; D000536:Aluminum Hydroxide; D010653:Phenylbutazone; D008274:Magnesium